Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOP-STAR: Tofogliflozin with or without sodium-restriction counseling for nocturia in type 2 diabetes
jRCTs051210212Completed
- Sponsor
- Kowa Company, Ltd.
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of tofogliflozin in type 2 diabetes mellitus (T2DM) and nocturia (2 arms), sponsored by Kowa Company, Ltd. Primary endpoint: Nocturnal urination frequency at week 12. Started Mar 2022; status: completed.
02
Drugs
tofogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)nocturia
Beyond the preview
Go deeper on jRCTs051210212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051210212.